Rep. Gilbert Ray Cisneros Jr. (D-CA) Buys ABT Stock
Rep. Gilbert Ray Cisneros Jr. made a new purchase of Abbott Laboratories stock in mid-September.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Ray Cisneros Jr. (D-CA) bought between $1,001 and $15,000 of Abbott Laboratories ($ABT) stock on September 18, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed October 12, 2026.
Since the trade, $ABT is down 1.3% after 1 week and up 2.9% to date (from the $101.98 close on Sep 18, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Ray Cisneros Jr. (D)
- Status:
- Member — House
- Party:
- Democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Oct 12, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Abbott Laboratories ($ABT) | Buy | Sep 18, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. View the original: STOCK Act disclosure (House Clerk)
ABT
Abbott Laboratories
Key Points
- On September 18, 2026, Rep. Gilbert Ray Cisneros Jr. bought shares of Abbott Laboratories valued between $1,001 and $15,000.
- As of October 16, 2026, Abbott's stock is trading around $104.70, which is below its 50-day moving average of $105.93 but above its 52-week low of $81.97.
- The company has a strong buy consensus from analysts with a mean price target of $120.71.
Get $ABT trade alerts by text
We text you when insiders, Congress or big funds trade $ABT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Abbott Laboratories alert may contain errors. Disclosures
Rep. Gilbert Ray Cisneros Jr. bought shares of Abbott Laboratories (NYSE: ABT) valued between $1,001 and $15,000 on September 18, 2026. This transaction was disclosed in a report filed under the STOCK Act on October 12, 2026.
Gilbert Ray Cisneros Jr. vs. the S&P 500
Hypothetical returns from Gilbert Ray Cisneros Jr.'s disclosed trades, not real profit or advice. How we model this.
What Changed in Gilbert Ray Cisneros Jr.'s Abbott Laboratories Position
Cisneros's recent purchase adds to his existing holdings, reflecting his continued interest in the healthcare sector.
Other Institutional Activity in Abbott Laboratories
Several institutional investors have shown activity in Abbott Laboratories recently. Blackrock Inc. boosted its holdings by 6,876,428 shares, bringing its total to about 152.6 million shares worth around $16 billion. Vanguard Capital Management LLC increased its stake by 801,938 shares, now holding approximately 113.8 million shares valued at about $11.9 billion. State Street Corporation added 1,352,749 shares, ending with roughly 80.9 million shares valued at about $8.5 billion. Charles Schwab Investment Management, Inc. increased its holdings significantly by 14,173,548 shares, totaling about 59.7 million shares worth around $6.3 billion. Vanguard Portfolio Management LLC also grew its position by 1,073,944 shares, now holding about 49.0 million shares valued at approximately $5.1 billion.
Abbott Laboratories Stock Up 2.5%
As of October 16, 2026, Abbott Laboratories is trading at approximately $104.70, which is below its 50-day moving average of $105.93 and about 20.7% lower than its 52-week high of $132.03. The stock is currently above its 52-week low of $81.97, indicating some resilience in a fluctuating market. Analysts have set a mean price target of $120.71, suggesting potential upside for the stock.
Recent Earnings
Abbott Laboratories reported trailing twelve-month revenue of approximately $46.6 billion, with a net margin of 11.6%. The company has shown a revenue growth of 13.0% year-over-year. Its next earnings report is scheduled for October 21, 2026, which could provide further insights into its performance.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
8 target cuts vs 0 raises.
-
EPS & revenue
EPS met estimates. Revenue beat estimates by 0.5%.
-
Profit surprise
EBITDA missed by 43 percent. Operating income missed by 19 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
8 target cuts.
-
Earnings quality
Gross margin up 3.7 points. Positive free cash flow.
Earnings Call Summary
Abbott completed its $2.4 billion acquisition of Exact Sciences on March 23 and is integrating the cancer diagnostics business into its portfolio. First quarter results came in slightly ahead, with sales of $11.2 billion, up 3.7 percent on a comparable basis, though the respiratory season was weaker than expected. The company is seeing early signs of volume recovery in Nutrition after price increases, expects Core Lab Diagnostics to accelerate, and is launching new cardiac devices like the Volt pulsed field ablation catheter and TactiFlex Duo. Management remains confident in second half acceleration but is being cautious on near term market conditions.
Guidance Abbott cut full year earnings guidance from $5.68 to $5.48 per share, reflecting $0.20 of dilution from the Exact Sciences acquisition. The company guided full year revenue growth of 6.5 percent to 7.5 percent on a comparable basis including Exact Sciences. For the second quarter, Abbott expects earnings of $1.25 to $1.31 per share. Management said they are being conservative on respiratory season assumptions and expect acceleration in the second half driven by Nutrition recovery, Core Lab Diagnostics growth, and Exact Sciences integration.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Abbott Laboratories
In recent insider activity, John G. Stratton, a Director at Abbott, bought 2,000 shares at an average price of $86.82 on May 7, 2026, totaling about $173,640. Other insiders, including Louis H. Morrone and CEO Robert B. Ford, have also been active, but their transactions involved selling shares.
Analysts Set New Price Targets
On August 13, 2026, Wolfe Research upgraded Abbott Laboratories to an Outperform rating with a target price of $130. Citigroup maintained a Buy rating with a target of $125 on August 14, while TD Cowen reiterated its Buy rating with a target of $135 on multiple occasions, emphasizing strong confidence in the company’s future performance. The consensus rating remains a strong buy with a mean target price of $120.71.
About Abbott Laboratories
Abbott Laboratories, based in Abbott Park, Illinois, develops and manufactures a wide range of healthcare products. These include medical devices, nutritional products, and diagnostic tools. The company operates across various segments, making it a key player in the healthcare industry.
Bottom Line
Investors should keep an eye on Abbott Laboratories as it prepares for its upcoming earnings report on October 21, 2026. Further disclosures from Rep. Cisneros and additional trading activity may also provide insights into market sentiment regarding this healthcare giant.
Related Filing Alerts
Source: Gilbert Ray Cisneros Jr.'s STOCK Act disclosure on $ABT (Sep 18, 2026). Read the original filing: STOCK Act disclosure (House Clerk). Written by software, not financial advice. How we make alerts